ArticlePloS one2025
Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic-inflammatory memory: the common pathological basis and therapeutic targets of metabolic syndrome.Reviews in endocrine & metabolic disorders · 2026Review
- DNA methylation and exosomes in relation to type 2 diabetes in Black South Africans: A pilot study.Global medical genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to steatohepatitis, being associated with inflammation, fibrosis, and immune cell interactions. Recent studies have reported an association between DNA methylation (DNAm) and MASLD. However, the relationship between DNAm and MASLD-related fibrosis is limited to liver tissue alone or focused on particular CpG sites. Moreover, despite the widely recognized sex differences in MASLD, studies that account for this variable remain limited. We performed whole-genome methylation sequencing (WGMS) on liver tissue and cell-free DNA (cfDNA) from patients with MASLD to investigate the association between fibrosis and DNAm. After initial filtering, the tissue and cfDNA data were further grouped by sex, and DNAm sites exceeding the minimum threshold for association with fibrosis were selected. Pathway analysis based on the genomic locations of CpG bins revealed both overlapping and distinct MASLD- and fibrosis-associated pathways across tissue and cfDNA, between males and females, and between intragenic and intergenic regions. Hepatic tissue deconvolution indicated the presence of immune cells and confirmed an increase in liver-derived cfDNA associated with fibrosis in cfDNA samples. Our study demonstrates the potential of WGMS as a platform for comprehensively observing the complex patterns of MASLD alterations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.